Quel Health Launches as a National Telehealth Company Prescribing GLP-1 Drugs Off-Label for Addiction

A new telehealth company is betting that a class of drugs best known for diabetes and weight loss can be repurposed to treat addiction, and it is building a national remote-care business around that idea before regulators have signed off on it. Quel Health, Inc. announced its launch on September 8, 2026, describing itself as the first national telehealth company built specifically around GLP-1 receptor agonists for addiction. The move sits at the intersection of three fast-moving telemedicine stories: the boom in remote GLP-1 prescribing, the growth of virtual addiction care, and a wave of research asking whether these metabolic drugs also blunt cravings for alcohol and other substances.

What Quel Health announced

According to the company's launch announcement, Quel Health, Inc. is a management services organization, not a medical practice, and clinical services are provided by licensed clinicians employed by affiliated professional entities. Quel says it operates a telehealth platform on which patients connect by video with addiction medicine providers from home, receive an evaluation and an individualized treatment plan, and continue with medication management and health tracking through video visits and app-based messaging. Quel states that care is available in 41 states and the District of Columbia, with national coverage planned by the end of 2026. The company did not disclose pricing in its announcement.

Quel named Caron Treatment Centers, a long-established addiction treatment nonprofit, as a Founding Strategic Partner, and said its program extends a GLP-1 addiction approach previously tested at Caron. The two organizations said they intend to explore collaboration on clinical protocols, research initiatives, professional education, and public awareness. Quel's co-founders are Marlene C. Lira, MPH, listed as chief executive officer, and Steven D. Klein, MD, PhD, listed as chief medical officer and described as an addiction medicine physician.

The key caveat: this is off-label prescribing

The central fact for readers is a regulatory one. GLP-1 receptor agonists, the class that includes semaglutide, are approved by the FDA for type 2 diabetes and for chronic weight management, and some products carry additional cardiovascular indications. The FDA has not approved any GLP-1 receptor agonist for alcohol use disorder, opioid use disorder, stimulant use disorder, or any other substance use disorder. Quel says as much in its own materials, stating that despite growing research interest the FDA has not approved GLP-1 receptor agonists for substance use indications.

Prescribing an approved drug for an unapproved use is legal and common in medicine, and it is called off-label prescribing. It is not the same as FDA endorsement of that use. Quel's chief medical officer, Steven Klein, described the approach to STAT News as using the drugs off-label under, in his words, the umbrella of addiction, whether that be food, sex, alcohol, or opioids. Quel says off-label prescribing at the company requires a thorough evaluation and an informed-consent process covering the current evidence, contraindications, potential known and unknown risks, and available treatment alternatives.

What the evidence actually shows

Interest in GLP-1 drugs for addiction is real and growing, but the published evidence is early and uneven, and most of it concerns alcohol rather than opioids or stimulants. In a randomized clinical trial published in JAMA Psychiatry in 2025, once-weekly semaglutide in adults with alcohol use disorder was associated with reduced weekly alcohol craving and fewer drinks on drinking days, and with greater reductions in heavy drinking over time compared with placebo. The same trial found no significant effect on the average number of drinks per calendar day or on the number of drinking days, and the authors framed the results as early findings that justify larger trials rather than as proof of a treatment.

A systematic review and meta-analysis published in the journal Diabetology and Metabolic Syndrome in January 2026 pooled five observational cohort studies and reported that GLP-1 receptor agonist use was associated with roughly a 28 percent lower risk of an alcohol use disorder diagnosis, with a smaller, non-significant reduction in alcohol-related hospitalization. The authors cautioned that the studies were observational, varied considerably in their methods, and were limited in number, and they concluded that larger, long-term randomized trials are needed to confirm the effect. In plain terms: the signal is interesting, it is not yet settled science, and evidence for substances other than alcohol is thinner still.

Why a telehealth company is doing this now

Quel's launch fits a broader pattern in telemedicine. Remote prescribing of GLP-1 drugs for weight loss scaled rapidly over the past few years, addiction treatment has increasingly moved to virtual visits, and dozens of clinical trials examining GLP-1 drugs for addiction are now registered on ClinicalTrials.gov, according to Quel. A company can combine an existing, widely used drug class with a telehealth delivery model and reach patients nationally without building brick-and-mortar clinics. That same efficiency is what draws scrutiny: it lets an off-label use spread quickly and directly to consumers before large confirmatory trials or an FDA indication exist.

What this means for patients and the field

For now, this is a company launch and a bet on emerging science, not a change in what the FDA has approved or in what clinical guidelines recommend. Even the parties involved describe the approach in cautious terms. Caron's chief executive, Steven Wall, said in the announcement that because the use of GLP-1 medications for substance use disorders remains investigational and off-label, rigorous clinical oversight, informed consent, and continued research are essential. GLP-1 drugs also carry documented side effects and contraindications in their approved uses, from common gastrointestinal effects to rarer risks, which do not disappear when the same drugs are used off-label.

Anyone weighing a telehealth program that prescribes GLP-1 drugs for addiction should treat the FDA approval status as a starting question, ask how a provider evaluates candidates and monitors them over time, and understand that the evidence base is still developing. Established, FDA-approved medications and behavioral treatments exist for some substance use disorders, and decisions about any of these options belong with a licensed clinician who knows the patient's history. This article is general information about a news development, not medical advice, and it is not an endorsement of Quel Health or of off-label GLP-1 use.